I am a Biotech Professional
For scientists and industry employees who want to see the bigger picture.
Relevant Courses:
-
This foundational course introduces learners to the biotech social contract, M&A game theory, and NPV modeling using in-depth examples.
32 Lessons Free -
If you are looking forward to a career in biotech, you are an investor. Time is money, you are investing your time in a company, and they will pay you in both cash and equity. Learn what equity is and how to value competing offers.
7 Lessons Free -
Our Finance Master Class was specifically designed as an advanced course for finance professionals in biotech hoping to level up in their careers. Learn value creation, financing strategy, and communication skills through an investor's lens.
16 Lessons Free -
Experts from the innovator, investor, and health plan communities provide analysis for biotech leaders on the impacts of new IRA legislation -- and propose fixes to make it better for patients and innovators.
6 Lessons Free -
RA Capital’s SABER is a detailed compendium of best practices drawn from the experiences of seasoned board members. In-depth examples (complete with data!) demonstrate how to take the principles in this guide from your laptop to the boardroom.
19 Lessons Free -
What we call "Series I" IPO principles are increasingly recognized as common sense and in the best interest of any strong company going public. Review our roadmap for running a rigorous price discovery and allocation process for yourself.
12 Lessons Free -
Proper insurance with low OOP costs is what makes anything in healthcare affordable. Investing new drugs that go generic without undue delay is how America saves lives and saves money.
10 Lessons Free -
Learn how public funding, incentives, and private funding function together to enable all of us to get what we want: new medicines.
4 Lessons Free -
What's the big deal about cutting the top-selling drugs down to just being reasonably profitable?
2 Lessons Free -
Drug price controls fail to solve affordability. And by killing the innovation conversation, they increase spending on healthcare in the long run. It's like putting off getting a mortgage to save money, but in the meantime your rent keeps rising.
7 Lessons Free -
How do our health technology assessment institutions value drugs - and how should they? Learn why we should prioritize generalized cost-effectiveness analysis (GCEA) over the outdated math used by ICER, NICE, and their peers.
5 Lessons Free -
Join Peter Kolchinsky, Tess Cameron, and Dan Lepanto (Senior Managing Director, SVB Securities) for a candid discussion on the array of tools a biotech board can employ in the midst of the current market downturn (June 2022).
1 Lessons Free
